GSK484, an inhibitor of peptidyl arginine deiminase 4, increases the radiosensitivity of colorectal cancer and inhibits neutrophil extracellular traps
The Journal of Gene Medicine · 2023-09 · 25 (9)
DOI: 10.1002/jgm.3530 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, online erschienen am 19.05.2023. Verfasst von Binbin Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Extracellular Traps, Imidazoles. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Introduction
Colorectal cancer (CRC) is the third most common malignancy and a major cause of cancer‐related deaths. Peptidyl arginine deiminase 4 (PAD4 or PADI4) is expressed in neutrophils that, when activated, can drive the formation of neutrophil extracellular traps (NETs). PAD4 has been found to be upregulated in CRC patients and to predict a poor prognosis. This study is aimed at exploring the role of PAD4 inhibitor (GSK484) in NET formation and radioresistance in CRC.
Methods
Reverse transcriptase quantitative polymerase chain reaction and western blotting were used to measure PAD4 expression in CRC tissues and cells. GSK484, an inhibitor of PAD4, was investigated in the following functional assays in vitro : western blotting, clonogenic survival, colony formation, TUNEL, flow cytometry and transwell assays. Nude mouse xenograft models were applied to evaluate the effect of GSK484 on tumor growth in CRC in vivo . The formation of NETs influenced by GSK484 was also investigated.
Results
We showed upregulation of PAD4 mRNA and protein in CRC tissues and cells. High expression of PAD4 was related to a poor prognosis in CRC patients. GSK484 treatment promoted the radiosensitivity of CRC cells and induced cell death by promoting DNA double‐strand breaks. Rescue experiments further verified that GSK484 inhibited the effects of PAD4 overexpression in irradiated CRC cells. Moreover, GSK484 injection strengthened the radiosensitivity of CRC and inhibited NET formation in vivo .
Conclusions
PAD4 inhibitor GSK484 promotes the radiosensitivity of CRC and inhibits NET formation in vivo and in vitro .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, Jiangsu, China.
ORCID-Profile: Shiwen Pan
Zitieren
APA
Wang, B., Su, X., Zhang, B., & Pan, S. (2023). GSK484, an inhibitor of peptidyl arginine deiminase 4, increases the radiosensitivity of colorectal cancer and inhibits neutrophil extracellular traps. The Journal of Gene Medicine, 25(9). https://doi.org/10.1002/jgm.3530
Vancouver
Wang B, Su X, Zhang B, Pan S. GSK484, an inhibitor of peptidyl arginine deiminase 4, increases the radiosensitivity of colorectal cancer and inhibits neutrophil extracellular traps. The Journal of Gene Medicine. 2023;25(9). doi:10.1002/jgm.3530
BibTeX
@article{Wang2023,
author = {Wang, Binbin and Su, Xiaojuan and Zhang, Bo and Pan, Shiwen},
title = {GSK484, an inhibitor of peptidyl arginine deiminase 4, increases the radiosensitivity of colorectal cancer and inhibits neutrophil extracellular traps},
journal = {The Journal of Gene Medicine},
year = {2023},
volume = {25},
number = {9},
doi = {10.1002/jgm.3530}
}
EUVIMED